Pathogen inactivation in cellular blood components: Clinical trials and implications of introduction to transfusion medicine

被引：15

作者：

AuBuchon, JP ^{[1
]}

机构：

[1] Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA

来源：

VOX SANGUINIS | 2002年 / 83卷

关键词：

D O I：

10.1111/j.1423-0410.2002.tb05316.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：271 / 275

页数：5

共 24 条

[1]

Aberle-Grasse JM, 2000, TRANSFUSION, V40, p3S

[2] SPECIFICITY AND CLINICAL-SIGNIFICANCE OF ANTI-LEX [J].

AUBUCHON, JP ;

DAVEY, RJ ;

ANDERSON, HJ ;

PATEL, S ;

STAVELY, LM ;

SCHOEPPNER, SL ;

ZAFIROPULOS, D .

TRANSFUSION, 1986, 26 (03) :302-303

[3]

AuBuchon JP, 2001, TRANSFUSION, V41, p1S

[4]

AuBuchon JP, 2000, BLOOD, V96, p818A

[5]

AUBUCHON JP, 2001, POLICY ALTERNATIVES

[6] Bacterial contamination of platelet concentrates: Incidence, significance, and prevention [J].

Blajchman, MA ;

Goldman, M .

SEMINARS IN HEMATOLOGY, 2001, 38 (04) :20-26

[7]

Busch MP, 2000, TRANSFUSION, V40, p25S

[8] Design of clinical trials to evaluate the efficacy of platelet transfusion:: The euroSPRITE trial for components treated with Helinx™ technology [J].

Cazenave, JP ;

Davis, K ;

Corash, L .

SEMINARS IN HEMATOLOGY, 2001, 38 (04) :46-54

[9] Inactivation of viruses, bacteria, protozoa, and leukocytes in platelet concentrates: Current research perspectives [J].

Corash, L .

TRANSFUSION MEDICINE REVIEWS, 1999, 13 (01) :18-30

[10]

Corash L, 2001, TRANSFUSION, V41, p38S

← 1 2 3 →